NCT07333066
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07333066
Title Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial. (REINFORCE)
Acronym REINFORCE
Recruitment Not yet recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | FRA | ESP | DEU


No variant requirements are available.